Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2029

Conditions
Esophagogastric Junction Adenocarcinoma
Interventions
DRUG

Sintilimab

Sintilimab 200mg iv drip. Qd D1 + Oxaliplatin 130/m2 iv drip. Qd D1 + Tegafur (Gimeracil and Oteracil Potassium Capsules) \[40mg/m2 if BSA \<1.25m2, 50mg/m2 if BSA ≥1.25m2 \& \<1.5m2, 60mg/m2 if BSA ≥1.5m2\] po. Bid D1-14 for three cycles

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER